Reducing labor time to decrease cell therapy manufacturing costs
We compare operator tasks for specific steps—such as cell expansion, mononuclear cell enrichment, and cryopreservation.
Automated and closed solutions for autologous CAR T cell therapy manufacturing
Why should you increase the level of automation in your auto CAR T manufacturing process?
One of the main challenges of manufacturing autologous CAR T cell therapy is the cost. Open, manual operations are error- and contamination-prone. And if you’re thinking of scaling, the probability of these errors might just scale with you. But you can reduce the risk—while keeping flexibility—with closed and automated systems. Automation brings formerly discrete steps together, saving you time and money. Plus, by standardizing your process, you’re one step closer to meeting regulatory requirements—and to safely delivering your therapies to patients.
Hover over the products below to learn more about the CAR T cell therapy workflow
Related content and resources
Regulating the CGT workflow to improve patient safety
A discussion on the latest regulatory developments that impact cell therapy manufacturing workflows.
Streamlining the CAR T cell therapy workflow
A robust workflow that can be adapted for cGMP compliance in commercial production.
Apheresis variability control in cell therapy manufacturing
Process control strategies to standardize MNC enrichment.
Using automated spinoculation for CAR T cell lentiviral transduction
A closed and automated solution for ex vivo gene transfer
Cell therapy process development and validation
Options to minimize risks and prepare for successful commercial production
Cryopreservation techniques to maximize T-cell viability
How fast and how far to freeze critical cell and gene therapies.
How to secure and standardize your cell expansion
Manual cell expansion is variable and prone to errors. Especially when multiple operators are involved. One solution? Automation.
Featured products
When it comes to producing high-quality cell therapies, using the right media and reagents is essential. With our portfolio of off-the-shelf solutions you can unlock opportunities to improve your process and get to market faster.
Learn moreDiscover how Cytiva – now together with Pall Life Sciences – can support your development and production needs across a variety of molecules and therapeutics.